Investigation of the clinical features and therapeutic methods for the management of inflammatory lacrimal punctum diseases
Purpose: To establish if there are different classes of inflammatory lacrimal punctum diseases (ILPDs) and to examine the various strategies by which they can be managed therapeutically.
Methods: Two hundred and fifty nine (259) patients with inflammatory punctum lacrimal disease were identified and used as subjects for this study. Each patient was carefully examined for evidence of morphology of lacrimal punctum which was confirmed mainly by lacrimal duct flushing and probing. Appropriate therapeutic managements were adopted for patients with other inflammatory conditions besides ILPD. The clinical effects of the various therapeutic strategies were documented. .
Results: Eighty-seven (87) patients out of the 259 (32.53 %) suffered from acute or chronic conjunctivitis while 66 patients (5.61 %) suffered from inflammatory lacrimal passage diseases. Patients with both conjunctivitis and lacrimal passage inflammation, patients with dry-eye symptoms, patients with just one of the conditions, and patients with mere evidence of superior punctalacrimalis represented 13.15, 14.19, 14.53, and 33.91 %, respectively. Mere evidence of inferior punctalacrimalis, and presence of acute inflammation were seen in 48.76 and 13.49 % of the 259 patients, respectively, while those with chronic inflammation lasting for 2.97 ± 0.13 years, comprised 86.51 %. Antibiotic eye drops were used for acute inflammation, while chronic inflammation was treated with antibiotic eye drops, lacrimal punctum expansion, pus elimination, and punctum-sparing canaliculotomy. Both therapeutic methods produced satisfactory curative effects.
Conclusion: The results show that satisfactory therapy of lacrimal punctum inflammation can be achieved if the right therapeutic agents and procedures are adopted based on clinical characteristics of the ILPD manifesting in the patient.
Keywords: Lacrimal punctum, Inflammatory disease, Conjunctivitis, Dry-eye symptoms
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.